• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

[基础知识] II期实验显示来曲唑联合依维莫斯治疗子宫内膜癌有效

[复制链接]
2152 4 seacat 发表于 2015-3-4 17:15:04 |

马上注册,结交更多好友,享用更多功能,让你轻松玩转社区。

您需要 登录 才可以下载或查看,没有账号?立即注册

x
Phase II Study of Everolimus and Letrozole in Patients With Recurrent Endometrial Carcinoma
http://jco.ascopubs.org/content/ ... 14.58.3401.abstract
Abstract
Purpose The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in endometrial cancer (EC). Hormonal manipulation leads to response in some patients with EC, but resistance derived from PI3K pathway activation has been documented. Targeting mammalian target of rapamycin (mTOR) may overcome endocrine resistance. We conducted a two-institution phase II trial of everolimus and letrozole in women with recurrent EC.

Patients and Methods Patients were considered incurable, had measurable disease, and were treated with up to two prior cytotoxic regimens. Everolimus was administered orally at 10 mg daily and letrozole was administered orally at 2.5 mg daily. Each cycle consisted of 4 weeks of therapy. Patients were treated until progression, toxicity, or complete response (CR). The primary end point was the clinical benefit rate (CBR), which was defined as CR, partial response, or stable disease (≥ 16 weeks) by RECIST 1.0 criteria. Translational studies were performed to correlate biomarkers with response.

Results Thirty-eight patients were enrolled (median age, 62 years; range, 24 to 82 years). Thirty-five patients were evaluable for response. The CBR was 40% (14 of 35 patients); the median number of cycles among responders was 15 (range, seven to 29 cycles). The confirmed objective response rate (RR) was 32% (11 of 35 patients; nine CRs and two partial responses; median, 15 cycles; range, eight to 29 cycles). Twenty percent of patients (seven of 35 patients) were taken off treatment after a prolonged CR and at the discretion of the treating clinician. None of the patients discontinued treatment as a result of toxicity. Serous histology was the best predictor of lack of response. Patients with endometrioid histology and CTNNB1 mutations responded well to everolimus and letrozole.

Conclusion Everolimus plus letrozole results in a high CBR and RR in patients with recurrent EC. Further development of this combination in recurrent endometrioid EC is under way.


来曲唑2.5mg每天,依维莫斯10mg每天。依维莫斯亚洲人如果不耐受可能要减量,8mg每天甚至5mg每天。
客观反应率32%,临床获益率40%。

来曲唑单用于子宫内膜癌有一定反应,联合依维莫斯似乎能提高客观反应率。
真想一觉醒来,我在小学教室对着小学同桌说:“我做了好长一个梦。”

4条精彩回复,最后回复于 2015-4-3 23:11

蔚蓝  初中二年级 发表于 2015-3-4 17:51:38 | 显示全部楼层 来自: 山东
患者的福音,版主辛苦了。
黎明的烛光  小学六年级 发表于 2015-3-18 22:32:57 | 显示全部楼层 来自: 北京
学习中,这个时候才感觉,学好英文很重要。
blsma  小学六年级 发表于 2015-3-27 23:15:17 | 显示全部楼层 来自: 中国
谢谢海猫,努力学习中
【枫】_Z2lZ6  禁止发言 发表于 2015-4-3 23:11:57 | 显示全部楼层 来自: 中国
提示: 作者被禁止或删除 内容自动屏蔽

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表